Corcept Therapeutics | CORT - Operating Profit


Corcept Therapeutics reported $4.49M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Alaunos Therapeutics USD -1.19M 432K Sep/2025
ANI Pharmaceuticals USD 29.13M 6.3M Dec/2025
Ardelyx USD 4.67M 19.07M Sep/2025
Assertio Holdings USD -3.05M 569K Sep/2024
Aurora Cannabis CAD -55.67M 35.45M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Canopy Growth CAD -14.3M 3.18M Sep/2025
Corcept Therapeutics USD 4.49M 5.73M Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Knight Therapeutics CAD 2.94M 2.4M Sep/2025
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Merck USD 6.24B 318M Dec/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Novartis USD 4.5B 363M Sep/2025
Novartis USD 4.58B 879M Sep/2025
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 3.19M 9.96M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Supernus Pharmaceuticals USD 13.82M 74.01M Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025